Efficacy and safety of 8-week glecaprevir/pibrentasvir in treatment-naive patients with chronic hepatitis c virus genotype 1, 2, 3, 4, 5, or 6 infection and compensated cirrhosis: EXPEDITION-8 complete results [abstract LP9]

Publication Type:

Conference Proceedings

Source:

Presented at Liver Meeting, 2019; November 8-12, Boston, Massachusetts (2019)
Top